<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6516">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01010633</url>
  </required_header>
  <id_info>
    <org_study_id>576</org_study_id>
    <nct_id>NCT01010633</nct_id>
  </id_info>
  <brief_title>Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to compare the safety and efficacy of loteprednol etabonate
      compared to vehicle for the treatment of postoperative inflammation and pain following
      cataract surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Resolution of Anterior Chamber Cells (ACC).</measure>
    <time_frame>Visit 5 (Postoperative day 8)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of Study eyes with complete resolution(Grade 0) of anterior chamber cells (ACC) for loteprednol and vehicle. Accumulation of white cells in aqueous graded on a scale of 0-4 where grade 0=no cells. Investigators assessed ACC using a slit lamp.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Grade 0 Pain</measure>
    <time_frame>Visit 5 (Postoperative Day 8)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of eyes with grade 0 ocular pain. Ocular pain, defined as a positive sensation of the eye, based on a 0-5 scale where grade 0 equaled no pain and grade 5 equaled severe pain. Ocular pain graded by participants.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resolution of Anterior Chamber Cells.</measure>
    <time_frame>At visits 4-7- postoperative day 3, 8,15 &amp; 18</time_frame>
    <safety_issue>No</safety_issue>
    <description>Study eyes with complete resolution of anterior chamber cells (ACC)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">406</enrollment>
  <condition>Inflammation</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Loteprednol Etabonate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loteprednol etabonate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle of loteprednol etabonate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle of Loteprednol Etabonate</intervention_name>
    <description>1 to 2 drops of vehicle administered into the study eye, 4 times a day for approximately 14 days.</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loteprednol Etabonate</intervention_name>
    <description>1 to 2 drops of study drug administered into the study eye, 4 times a day for approximately 14 days.</description>
    <arm_group_label>Loteprednol Etabonate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who are at least 18 years of age.

          -  Subjects who are candidates for routine, uncomplicated cataract surgery.

          -  Subjects who, in the Investigator's opinion, have potential postoperative pinholed
             Snellen visual acuity (VA) of at least 20/200 in the study eye.

        Exclusion Criteria:

          -  Subjects who have known hypersensitivity or contraindication to the study drug or
             components.

          -  Subjects with a severe/serious ocular condition, or any other unstable medical
             condition, that in the investigator's opinion may preclude study treatment or
             follow-up.

          -  Subjects with elevated intraocular pressure (&gt;/= 21mm Hg), uncontrolled glaucoma, or
             being treated for glaucoma in the study eye.

          -  Subjects who are monocular or have pinholed Snellen VA 20/200 or worse in the
             non-study eye.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura Trusso</last_name>
    <role>Study Director</role>
    <affiliation>Bausch &amp; Lomb Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bausch &amp; Lomb, Inc.</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <lastchanged_date>December 8, 2011</lastchanged_date>
  <firstreceived_date>November 6, 2009</firstreceived_date>
  <firstreceived_results_date>August 30, 2011</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Loteprednol etabonate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was initiated at 20 clinics in the United States (US). Three sites did not enroll any participants. The study was conducted at the remaining 17 sites. First participant was enrolled 11/23/2009 and last participant completed 6/25/2010.</recruitment_details>
      <pre_assignment_details>406 participants eligible for cataract surgery were enrolled in the study (safety population). 397 participants completed the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Loteprednol</title>
          <description>Loteprednol etabonate 0.5%</description>
        </group>
        <group group_id="P2">
          <title>Vehicle</title>
          <description>Vehicle of loteprednol etabonate</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="203"/>
                <participants group_id="P2" count="203"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="199"/>
                <participants group_id="P2" count="198"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Loteprednol</title>
          <description>Loteprednol etabonate 0.5%</description>
        </group>
        <group group_id="B2">
          <title>Vehicle</title>
          <description>Vehicle of loteprednol etabonate</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="203"/>
                <measurement group_id="B2" value="203"/>
                <measurement group_id="B3" value="406"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="69.3" spread="8.73"/>
                <measurement group_id="B2" value="69.0" spread="9.80"/>
                <measurement group_id="B3" value="69.1" spread="9.27"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="109"/>
                <measurement group_id="B2" value="122"/>
                <measurement group_id="B3" value="231"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="94"/>
                <measurement group_id="B2" value="81"/>
                <measurement group_id="B3" value="175"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American Indian or Alaska Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="5"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
                <measurement group_id="B2" value="16"/>
                <measurement group_id="B3" value="36"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="176"/>
                <measurement group_id="B2" value="182"/>
                <measurement group_id="B3" value="358"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Other</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Resolution of Anterior Chamber Cells (ACC).</title>
        <description>Number of Study eyes with complete resolution(Grade 0) of anterior chamber cells (ACC) for loteprednol and vehicle. Accumulation of white cells in aqueous graded on a scale of 0-4 where grade 0=no cells. Investigators assessed ACC using a slit lamp.</description>
        <time_frame>Visit 5 (Postoperative day 8)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent to treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Loteprednol</title>
            <description>Loteprednol Etabonate 0.5%</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Vehicle of Loteprednol Etabonate</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="203"/>
                  <measurement group_id="O2" value="203"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Eyes analyzed</title>
            <units>Eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="203"/>
                  <measurement group_id="O2" value="203"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Resolution of Anterior Chamber Cells (ACC).</title>
            <description>Number of Study eyes with complete resolution(Grade 0) of anterior chamber cells (ACC) for loteprednol and vehicle. Accumulation of white cells in aqueous graded on a scale of 0-4 where grade 0=no cells. Investigators assessed ACC using a slit lamp.</description>
            <units>Eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="62"/>
                  <measurement group_id="O2" value="33"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>14.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.7</ci_lower_limit>
            <ci_upper_limit>22.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Resolution of Anterior Chamber Cells.</title>
        <description>Study eyes with complete resolution of anterior chamber cells (ACC)</description>
        <time_frame>At visits 4-7- postoperative day 3, 8,15 &amp; 18</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Loteprednol</title>
            <description>Loteprednol Etabonate 0.5%</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Vehicle of Loteprednol Etabonate</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="203"/>
                  <measurement group_id="O2" value="203"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Resolution of Anterior Chamber Cells.</title>
            <description>Study eyes with complete resolution of anterior chamber cells (ACC)</description>
            <units>Eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Visit 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Visit 5</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="62"/>
                  <measurement group_id="O2" value="33"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Visit 6</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="102"/>
                  <measurement group_id="O2" value="44"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Visit 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="96"/>
                  <measurement group_id="O2" value="45"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Grade 0 Pain</title>
        <description>Number of eyes with grade 0 ocular pain. Ocular pain, defined as a positive sensation of the eye, based on a 0-5 scale where grade 0 equaled no pain and grade 5 equaled severe pain. Ocular pain graded by participants.</description>
        <time_frame>Visit 5 (Postoperative Day 8)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent to treat population (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Loteprednol</title>
            <description>Loteprednol Etabonate 0.5%</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Vehicle of Loteprednol Etabonate</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="203"/>
                  <measurement group_id="O2" value="203"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Eyes analyzed</title>
            <units>Eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="203"/>
                  <measurement group_id="O2" value="203"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Grade 0 Pain</title>
            <description>Number of eyes with grade 0 ocular pain. Ocular pain, defined as a positive sensation of the eye, based on a 0-5 scale where grade 0 equaled no pain and grade 5 equaled severe pain. Ocular pain graded by participants.</description>
            <units>Eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="148"/>
                  <measurement group_id="O2" value="85"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>31.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>21.4</ci_lower_limit>
            <ci_upper_limit>40.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Visit 3 post-operative day 1 thru visit 7 postoperative day 18</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Loteprednol</title>
          <description>Loteprednol etabonate 0.5%</description>
        </group>
        <group group_id="E2">
          <title>Vehicle</title>
          <description>Vehicle of loteprednol etabonate</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Heart Failure</sub_title>
                <description>SAEs were unrelated to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cystoid Macular Edema</sub_title>
                <description>Unrelated to study drug, but probably related to study procedure</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <description>The event is serious, unexpected, unrelated to the study drug and the study procedure but rather possibly related to a concomitant illness in a predisposed patient</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All study data generated as a result of this study will be regarded as confidential, until appropriate analysis and review by the Sponsor or its designee and the Investigator(s) are completed. The results of the study may be published or presented by the Investigator(s)after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tuyen Ong, MD, MRCOphth</name_or_title>
      <organization>Bausch &amp; Lomb Incorporated</organization>
      <phone>(973) 360-6389</phone>
      <email>tuyen.ong@bausch.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
